RJFSA
OTLK icon

Raymond James Financial Services Advisors’s Outlook Therapeutics OTLK Stock Holding History

Raymond James Financial Services Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,500
Closed -$22K – 3049
2020
Q3 		$22K Buy
+1,500
New +$33.4K ﹤0.01% 2817

Other funds holding OTLK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James Financial Services Advisors's OTLK Position: Q4 2020 in Review

Raymond James Financial Services Advisors sold out of Outlook Therapeutics (OTLK) in Q4 2020, closing a stake of 1,500 shares — an estimated $22K sold.

Raymond James Financial Services Advisors first reported a position in OTLK in Q3 2020 and held it in 1 quarter. The position peaked at $22K in Q3 2020. 30 funds tracked by Wall St. Rank hold OTLK as of Q4 2020.

  • Raymond James Financial Services Advisors reported no remaining Outlook Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 1,500 Outlook Therapeutics shares in Q4 2020, an estimated $22K.
  • Raymond James Financial Services Advisors first reported a position in Outlook Therapeutics in Q3 2020 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Outlook Therapeutics position peaked at $22K in Q3 2020.
  • 30 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.